Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
49,625,327
-
Number of holders
-
19
-
Total 13F shares, excl. options
-
5,370,044
-
Shares change
-
-108,224
-
Total reported value, excl. options
-
$6,766,125
-
Value change
-
-$142,743
-
Number of buys
-
5
-
Number of sells
-
-8
-
Price
-
$1.26
Significant Holders of Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share (CADL) as of Q2 2023
22 filings reported holding CADL - Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share as of Q2 2023.
Candel Therapeutics, Inc. - Common stock, par value $0.0001 per share (CADL) has 19 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5,370,044 shares
of 49,625,327 outstanding shares and own 11% of the company stock.
Largest 10 shareholders include Northpond Ventures, LLC (1,935,215 shares), FRANKLIN RESOURCES INC (1,125,000 shares), Sands Capital Ventures, LLC (811,737 shares), FMR LLC (452,557 shares), VANGUARD GROUP INC (405,755 shares), BRIDGEWAY CAPITAL MANAGEMENT, LLC (132,595 shares), GEODE CAPITAL MANAGEMENT, LLC (131,203 shares), CITIGROUP INC (118,612 shares), Baystate Wealth Management LLC (100,540 shares), and BlackRock Inc. (51,823 shares).
This table shows the top 19 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.